Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids

Berman, Brian; Kaufman, Joely

doi:10.1067/mjd.2002.126585

Cited by 164 publications

(115 citation statements)

References 14 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…In addition, imiquimod alters the expression of apoptosis-associated genes (100). Therefore, it has been used in an attempt to reduce keloid recurrence after excision and was reported to have positive effects on the recurrence rate of keloids after postoperative application (101). However, in a prospective, double-blind, placebo-controlled pilot study in which imiquimod 5% cream was applied nightly for 2 weeks before being given 3 times/week under occlusion for 1 month postoperatively, no significant difference in keloid recurrence rates between groups could be detected (102).…”

Section: Emerging Prophylactic Approachesmentioning

confidence: 99%

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Gauglitz

Körting

Pavicic

et al. 2010

Mol Med

1,176

1,012

View full text Add to dashboard Cite

Excessive scars form as a result of aberrations of physiologic wound healing and may arise following any insult to the deep dermis. By causing pain, pruritus and contractures, excessive scarring significantly affects the patient's quality of life, both physically and psychologically. Multiple studies on hypertrophic scar and keloid formation have been conducted for decades and have led to a plethora of therapeutic strategies to prevent or attenuate excessive scar formation. However, most therapeutic approaches remain clinically unsatisfactory, most likely owing to poor understanding of the complex mechanisms underlying the processes of scarring and wound contraction. In this review we summarize the current understanding of the pathophysiology underlying keloid and hypertrophic scar formation and discuss established treatments and novel therapeutic strategies.

show abstract

Section: Emerging Prophylactic Approachesmentioning

confidence: 99%

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Gauglitz

Körting

Pavicic

et al. 2010

Mol Med

1,176

1,012

View full text Add to dashboard Cite

show abstract

“…Topical imiquimod has also been used in a variety of different skin disorders including nodular and superficial BCC (29), in situ and invasive SCC (30)(31), lentigo maligna (32), lentigo maligna melanoma (33), keratoacanthomas (34), primary cutaneous CD30 positive anaplastic large cell lymphoma (35), mycosis fungoides (36), extramammary Paget's disease (37), cutaneous melanoma metastases (38), cutaneous warts and molluscum contagiosum (39), stucco keratosis (40), cutaneous leishmaniasis (41) and keloids (42).…”

Section: Imiquimod: a Promising Topical Immunostimulatory Agent For Dmentioning

confidence: 99%

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Trakatelli

Katsanos

Ulrich

et al. 2010

Int J Immunopathol Pharmacol

View full text Add to dashboard Cite

The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.The past decades have seen unprecedented progress in the development of solid organ transplantation as a therapeutic choice for endstage organ disease. Organ Transplant Recipients (OTR) live longer, have a good quality of life and represent a rapidly growing population of people with specific medical needs. As the number of solid organ transplants continues to rise, so too does the number of various infections including human papillomavirus (HPV) infections and skin cancers in OTR. Consequently, physicians will be called upon to manage these diseases in the sensitive OTR population and to develop novel therapeutic and preventive strategies to better deal with them.The clinical efficacy of imiquimod 5% cream (a topical therapy approved for genital warts, actinic keratoses and superficial basal cell carcinoma) stems from stimulation ofinnate and cell-mediated immune responses, resulting in antiviral, antiproliferative and antitumor activity. Because of these properties, imiquimod and other members of this family of immune response modifiers are potential agents for treatment of conditions where the immune system can affect the regression of the disease (1). In light of the role of systemic immunosupression in the development of cutaneous infections and neoplasms in OTR, the use of imiquimod to locally stimulate immune responses against cancerous, pre-cancerous

show abstract

“…Es existieren positive Fallberichte bzw. Studien [27], jedoch sind größere Fallzahlen und längere Beobachtungszeiträume über Jahre notwendig, um eine klare Empfehlung für diese Therapie− möglichkeit aussprechen zu können. Gerade an Lokalisationen mit geringer Spannung wie den Ohren konnte über einen Beob− achtungszeitraum von 6 bis 9 Monaten eine sehr niedrige Rezi− divrate von 2,9 % festgestellt werden, während es im Brustbe− reich bei 83,3 % der Patienten zum Rezidiv kam [28].…”

Section: Imiquimodunclassified

Narbe und Keloid – und nun?

Heinlin¹,

Landthaler²,

Karrer³

2008

Akt Dermatol

View full text Add to dashboard Cite

Pilot study of the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids

Cited by 164 publications

References 14 publications

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Hypertrophic Scarring and Keloids: Pathomechanisms and Current and Emerging Treatment Strategies

Efforts to Counteract Locally the Effects of Systemic Immunosupression: A Review on the Use of Imiquimod, a Topical Immunostimulator in Organ Transplant Recipients

Narbe und Keloid – und nun?

Contact Info

Product

Resources

About